Base de dados : MEDLINE
Pesquisa : A11.284.183.200 [Categoria DeCS]
Referências encontradas : 124 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 13 ir para página                         

  1 / 124 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27829029
[Au] Autor:Mansfeldt CB; Heavner GW; Rowe AR; Hayete B; Church BW; Richardson RE
[Ad] Endereço:Department of Civil and Environmental Engineering, Cornell University, Ithaca, NY, United States of America.
[Ti] Título:Inferring Gene Networks for Strains of Dehalococcoides Highlights Conserved Relationships between Genes Encoding Core Catabolic and Cell-Wall Structural Proteins.
[So] Source:PLoS One;11(11):e0166234, 2016.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The interpretation of high-throughput gene expression data for non-model microorganisms remains obscured because of the high fraction of hypothetical genes and the limited number of methods for the robust inference of gene networks. Therefore, to elucidate gene-gene and gene-condition linkages in the bioremediation-important genus Dehalococcoides, we applied a Bayesian inference strategy called Reverse Engineering/Forward Simulation (REFS™) on transcriptomic data collected from two organohalide-respiring communities containing different Dehalococcoides mccartyi strains: the Cornell University mixed community D2 and the commercially available KB-1® bioaugmentation culture. In total, 49 and 24 microarray datasets were included in the REFS™ analysis to generate an ensemble of 1,000 networks for the Dehalococcoides population in the Cornell D2 and KB-1® culture, respectively. Considering only linkages that appeared in the consensus network for each culture (exceeding the determined frequency cutoff of ≥ 60%), the resulting Cornell D2 and KB-1® consensus networks maintained 1,105 nodes (genes or conditions) with 974 edges and 1,714 nodes with 1,455 edges, respectively. These consensus networks captured multiple strong and biologically informative relationships. One of the main highlighted relationships shared between these two cultures was a direct edge between the transcript encoding for the major reductive dehalogenase (tceA (D2) or vcrA (KB-1®)) and the transcript for the putative S-layer cell wall protein (DET1407 (D2) or KB1_1396 (KB-1®)). Additionally, transcripts for two key oxidoreductases (a [Ni Fe] hydrogenase, Hup, and a protein with similarity to a formate dehydrogenase, "Fdh") were strongly linked, generalizing a strong relationship noted previously for Dehalococcoides mccartyi strain 195 to multiple strains of Dehalococcoides. Notably, the pangenome array utilized when monitoring the KB-1® culture was capable of resolving signals from multiple strains, and the network inference engine was able to reconstruct gene networks in the distinct strain populations.
[Mh] Termos MeSH primário: Esqueleto da Parede Celular/genética
Parede Celular/genética
Chloroflexi/genética
Redes Reguladoras de Genes/genética
Metabolismo/genética
[Mh] Termos MeSH secundário: Chloroflexi/metabolismo
Sequência Consenso/genética
Análise de Sequência com Séries de Oligonucleotídeos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Cell Wall Skeleton)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170626
[Lr] Data última revisão:
170626
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161110
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0166234


  2 / 124 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:27803478
[Au] Autor:Nakamura T
[Ad] Endereço:Laboratory for Molecular Design of Pharmaceutics, Faculty of Pharmaceutical Sciences, Hokkaido University.
[Ti] Título:Development of a Drug Delivery System for Cancer Immunotherapy.
[So] Source:Yakugaku Zasshi;136(11):1477-1484, 2016.
[Is] ISSN:1347-5231
[Cp] País de publicação:Japan
[La] Idioma:jpn
[Ab] Resumo:Delivery systems are a powerful technology for enhancing the effect of cancer immunotherapy. We have been in the process of developing lipid-based delivery systems for controlling the physical properties and dynamics of immunofunctional molecules such as antigens and adjuvants. The lipid nanoparticulation of these molecules improves their physical properties, resulting in a good water dispensability, greater stability, and small size. The cell wall skeleton of bacille Calmette-Guerin (BCG-CWS) could be used to replace live BCG as a drug for treating bladder cancer, but problems associated with the physical properties of BCG-CWS have prevented its use. To overcome such problems, we developed a novel packaging method that permits BCG-CWS to be encapsulated into lipid nanoparticles, which induce antitumor responses against bladder cancer. Lipid nanoparticulation also improves the intracellular trafficking and biodistribution of immunofunctional molecules. Cyclic di-GMP (c-di-GMP) is an adjuvant that is recognized by the cytosolic sensor. However, c-di-GMP cannot pass through the cell membrane. We encapsulated c-di-GMP into lipid nanoparticles containing a pH-responsive lipid that was developed in our laboratory and achieved efficient cytosolic delivery and the induction of antitumor immunity. Furthermore, we are attempting to control the functions of immune cells by RNA interference. We have recently succeeded in the efficient delivery of small interfering RNA into mouse dendritic cells (DCs), which led to the enhancement of antitumor activity of DCs. In this review, our recent efforts regarding cancer immunotherapy using lipid-based nanoparticles are reviewed.
[Mh] Termos MeSH primário: Sistemas de Liberação de Medicamentos
Desenho de Drogas
Imunoterapia
Lipídeos
Nanopartículas
Neoplasias/terapia
[Mh] Termos MeSH secundário: Adjuvantes Imunológicos
Animais
Esqueleto da Parede Celular
GMP Cíclico/análogos & derivados
Células Dendríticas
Seres Humanos
Camundongos
Mycobacterium bovis
Interferência de RNA
Neoplasias da Bexiga Urinária/terapia
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Adjuvants, Immunologic); 0 (Cell Wall Skeleton); 0 (Lipids); 61093-23-0 (bis(3',5')-cyclic diguanylic acid); H2D2X058MU (Cyclic GMP)
[Em] Mês de entrada:1704
[Cu] Atualização por classe:171017
[Lr] Data última revisão:
171017
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161103
[St] Status:MEDLINE


  3 / 124 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:25315488
[Au] Autor:Nakamura T; Fukiage M; Suzuki Y; Yano I; Miyazaki J; Nishiyama H; Akaza H; Harashima H
[Ad] Endereço:Faculty of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan.
[Ti] Título:Mechanism responsible for the antitumor effect of BCG-CWS using the LEEL method in a mouse bladder cancer model.
[So] Source:J Control Release;196:161-7, 2014 Dec 28.
[Is] ISSN:1873-4995
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:We previously reported on the development of a water soluble formulation of the cell wall skeleton of BCG (BCG-CWS), a major immune active center of BCG, by encapsulating it into a nanoparticle (CWS-NP). The CWS-NP allowed us to clarify the machinery associated with the BCG mediated anti-bladder tumor effect, especially the roles of bladder cancer cells and dendritic cells (DCs) in the initial step, which remains poorly understood. We show herein that the internalization of BCG-CWS by bladder cancer cells, but not DCs, is indispensable for the induction of an antitumor effect against bladder cancer. Tumor growth was significantly inhibited in mice that had been inoculated with mouse bladder cancer (MBT-2) cells containing internalized BCG-CWS. On the other hand, the internalization of BCG-CWS by DCs had only a minor effect on inducing an antitumor effect against MBT-2 tumors. This was clarified for the first time by using the CWS-NP. This finding provides insights into our understanding of the role of bladder cancer cells and DCs in BCG therapy against bladder cancer.
[Mh] Termos MeSH primário: Antineoplásicos/farmacologia
Vacina BCG/farmacologia
Esqueleto da Parede Celular/farmacologia
Neoplasias da Bexiga Urinária/tratamento farmacológico
[Mh] Termos MeSH secundário: Animais
Linhagem Celular Tumoral
Células Dendríticas/efeitos dos fármacos
Emulsões
Feminino
Contagem de Leucócitos
Lipídeos/química
Camundongos
Camundongos Endogâmicos C3H
Ensaios Antitumorais Modelo de Xenoenxerto
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Antineoplastic Agents); 0 (BCG Vaccine); 0 (Cell Wall Skeleton); 0 (Emulsions); 0 (Lipids)
[Em] Mês de entrada:1508
[Cu] Atualização por classe:141216
[Lr] Data última revisão:
141216
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:141016
[St] Status:MEDLINE


  4 / 124 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:24389133
[Au] Autor:Nakamura T; Fukiage M; Higuchi M; Nakaya A; Yano I; Miyazaki J; Nishiyama H; Akaza H; Ito T; Hosokawa H; Nakayama T; Harashima H
[Ad] Endereço:Faculty of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan.
[Ti] Título:Nanoparticulation of BCG-CWS for application to bladder cancer therapy.
[So] Source:J Control Release;176:44-53, 2014 Feb 28.
[Is] ISSN:1873-4995
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:The Mycobacterium bovis Bacille Calmette-Guerin cell wall skeleton (BCG-CWS) could be used to replace live BCG as a bladder cancer drug. However, because BCG-CWS is poorly soluble, has a strong-negative charge, very high molecular weight and heterogeneity in size of tens of µm, it cannot be used in such an application. We report herein on the development of a novel packaging method that permits BCG-CWS to be encapsulated into 166nm-sized lipid particles. The BCG-CWS encapsulated nano particle (CWS-NP) has a high uniformity and can be easily dispersed. Thus, it has the potential for use as a packaging method that would advance the scope of applications of BCG-CWS as a bladder cancer drug. In a functional evaluation, CWS-NP was efficiently taken up by mouse bladder tumor (MBT-2) cells in vitro and inhibited tumor growth in mice bearing MBT-2 tumors. Moreover, intravesically administered CWS-NP showed significant antitumor effects in a rat model with naturally developed bladder cancer. An enhancement in Th1 differentiation by CWS-NP was also confirmed in human T cells. In conclusion, CWS-NP represents a promising delivery system for BCG-CWS for clinical development as a potent bladder cancer drug.
[Mh] Termos MeSH primário: Antineoplásicos/administração & dosagem
Esqueleto da Parede Celular/administração & dosagem
Mycobacterium bovis
Nanopartículas/administração & dosagem
Neoplasias da Bexiga Urinária/tratamento farmacológico
[Mh] Termos MeSH secundário: Adulto
Animais
Butilidroxibutilnitrosamina
Diferenciação Celular/efeitos dos fármacos
Linhagem Celular Tumoral
Células Cultivadas
Feminino
Seres Humanos
Masculino
Camundongos
Camundongos Endogâmicos C3H
Ratos
Ratos Endogâmicos F344
Linfócitos T/citologia
Linfócitos T/efeitos dos fármacos
Neoplasias da Bexiga Urinária/induzido quimicamente
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Antineoplastic Agents); 0 (Cell Wall Skeleton); 3817-11-6 (Butylhydroxybutylnitrosamine)
[Em] Mês de entrada:1410
[Cu] Atualização por classe:140225
[Lr] Data última revisão:
140225
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:140107
[St] Status:MEDLINE


  5 / 124 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:23686120
[Au] Autor:Cargnelutti DE; Sanchez MA; Alvarez P; Boado L; Mattion N; Scodeller EA
[Ad] Endereço:Institute of Experimental Medicine and Biology of Cuyo (IMBECU) CCT-Mendoza-CONICET, Mendoza, Argentina. diegocargnelutti@hotmail.com
[Ti] Título:Enhancement of Th1 immune responses to recombinant influenza nucleoprotein by Ribi adjuvant.
[So] Source:New Microbiol;36(2):145-51, 2013 Apr.
[Is] ISSN:1121-7138
[Cp] País de publicação:Italy
[La] Idioma:eng
[Ab] Resumo:A broad coverage influenza vaccine against multiple viral strains based on the viral nucleoprotein (NP) is a goal pursued by many laboratories. If the goal is to formulate the vaccine with recombinant NP it is essential to count on adjuvants capable of inducing cellular immunity. This work have studied the effect of the monophosphoryl lipid A and trehalose dimycolate, known as the Ribi Adjuvant System (RAS), in the immune response induced in mice immunized with recombinant NP. The NP was formulated with RAS and used to immunize BALB/c mice. Immunizations with NP-RAS increased the humoral and cellular immune responses compared to unadjuvanted NP. The predominant antibody isotype was IgG2a, suggesting the development of a Th1 response. Analysis of the cytokines from mice immunized with NP-RAS showed a significant increase in the production of IFN-g and a decreased production of IL-10 and IL-4 compared to controls without RAS. These results are similar to those usually obtained using Freund's adjuvant, known to induce Th1 and CTL responses when co-administered with purified proteins, and suggest that a similar approach may be possible to enhance the performance of a T-cell vaccine containing NP.
[Mh] Termos MeSH primário: Esqueleto da Parede Celular/administração & dosagem
Fatores Corda/administração & dosagem
Influenza Humana/imunologia
Lipídeo A/análogos & derivados
Proteínas de Ligação a RNA/imunologia
Células Th1/imunologia
Proteínas do Core Viral/imunologia
[Mh] Termos MeSH secundário: Animais
Anticorpos Antivirais/imunologia
Esqueleto da Parede Celular/imunologia
Fatores Corda/imunologia
Feminino
Seres Humanos
Imunidade Celular
Imunização
Vacinas contra Influenza/administração & dosagem
Vacinas contra Influenza/genética
Vacinas contra Influenza/imunologia
Influenza Humana/prevenção & controle
Influenza Humana/virologia
Interferon gama/imunologia
Interleucina-10/imunologia
Interleucina-4/imunologia
Lipídeo A/administração & dosagem
Lipídeo A/imunologia
Camundongos
Camundongos Endogâmicos BALB C
Proteínas de Ligação a RNA/administração & dosagem
Proteínas de Ligação a RNA/genética
Linfócitos T Citotóxicos/imunologia
Proteínas do Core Viral/administração & dosagem
Proteínas do Core Viral/genética
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Antibodies, Viral); 0 (Cell Wall Skeleton); 0 (Cord Factors); 0 (Influenza Vaccines); 0 (Lipid A); 0 (NP protein, Influenza A virus); 0 (RNA-Binding Proteins); 0 (Ribi adjuvant); 0 (Viral Core Proteins); 130068-27-8 (Interleukin-10); 207137-56-2 (Interleukin-4); 82115-62-6 (Interferon-gamma)
[Em] Mês de entrada:1308
[Cu] Atualização por classe:130520
[Lr] Data última revisão:
130520
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:130521
[St] Status:MEDLINE


  6 / 124 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:23006993
[Au] Autor:Miyauchi M; Murata M; Fukushima A; Sato T; Nakagawa M; Fujii T; Koseki N; Chiba N; Kashiwazaki Y
[Ad] Endereço:Pharmacology Research Laboratories, Dainippon Sumitomo Pharma Co., Ltd., Osaka-shi, Osaka, Japan. masanori-miyauchi@ds-pharma.co.jp
[Ti] Título:Optimization of cell-wall skeleton derived from Mycobacterium bovis BCG Tokyo 172 (SMP-105) emulsion in delayed-type hypersensitivity and antitumor models.
[So] Source:Drug Discov Ther;6(4):218-25, 2012 Aug.
[Is] ISSN:1881-7831
[Cp] País de publicação:Japan
[La] Idioma:eng
[Ab] Resumo:Cell-wall skeleton prepared from Mycobacterium bovis BCG (BCG-CWS) is known as a potent adjuvant and has been shown to possess antitumor activity in many non-clinical and clinical studies. As there are no approved BCG-CWS formulations for cancer therapy, we investigated the potential for cancer immunotherapy of SMP-105, our originally produced BCG-CWS. For optimizing SMP-105 emulsion, we compared the effects of drakeoland squalane-based SMP-105 emulsions on IFN-γ production in rats and evaluated their ability to induce skin reaction in guinea pigs. Both emulsions had the same activity in both experiments. We selected squalane as base material and produced two types of squalane-based formulations (vialed emulsion and pumped emulsion) that can easily be prepared as oil-in-water emulsions. Although the vialed emulsion showed the same pattern of distribution as a usual homogenized emulsion, the pumped emulsion showed more uniform distribution than the other two emulsions. Whereas both emulsions enhanced strong delayed type hypersensitivity (DTH) reaction in a mouse model, the pumped emulsion induced slightly smaller edema. Data on oil droplet size distribution suggest that few micrometer oil droplet size might be appropriate for oil-in-water microemulsion of SMP-105. The antitumor potency of SMP-105 emulsion was stronger than that of some of the launched toll-like receptor (TLR) agonists (Aldara cream, Picibanil, and Immunobladder). Aldara and Picibanil showed limited antitumor effectiveness, while Immunobladder had almost the same effect as SMP-105 at the highest dose, but needed about 10 times the amount of SMP-105. These findings first indicate that SMP-105 has great potential in cancer immunotherapy.
[Mh] Termos MeSH primário: Adjuvantes Imunológicos/farmacologia
Antineoplásicos/farmacologia
Esqueleto da Parede Celular/farmacologia
Mycobacterium bovis/química
[Mh] Termos MeSH secundário: Adjuvantes Imunológicos/efeitos adversos
Adjuvantes Imunológicos/isolamento & purificação
Animais
Antineoplásicos/efeitos adversos
Antineoplásicos/isolamento & purificação
Linhagem Celular Tumoral
Esqueleto da Parede Celular/efeitos adversos
Esqueleto da Parede Celular/isolamento & purificação
Emulsões
Feminino
Cobaias
Hipersensibilidade Tardia/imunologia
Imunoterapia
Interferon gama/biossíntese
Interferon gama/imunologia
Neoplasias Hepáticas Experimentais/tratamento farmacológico
Neoplasias Hepáticas Experimentais/imunologia
Masculino
Camundongos
Camundongos Endogâmicos C57BL
Ratos
Ratos Endogâmicos Lew
Ensaios Antitumorais Modelo de Xenoenxerto
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Adjuvants, Immunologic); 0 (Antineoplastic Agents); 0 (Cell Wall Skeleton); 0 (Emulsions); 82115-62-6 (Interferon-gamma)
[Em] Mês de entrada:1304
[Cu] Atualização por classe:120925
[Lr] Data última revisão:
120925
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:120926
[St] Status:MEDLINE


  7 / 124 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:21397337
[Au] Autor:Mohammadi AA; Tetro JA; Filion LG
[Ad] Endereço:Department of Biochemistry Microbiology and Immunology, Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada.
[Ti] Título:Epitope selection to male specific antigens for sex selection in swine.
[So] Source:J Reprod Immunol;89(1):46-54, 2011 Apr.
[Is] ISSN:1872-7603
[Cp] País de publicação:Ireland
[La] Idioma:eng
[Ab] Resumo:Immunological approaches to gender selection have been contemplated since the discovery of the family of male-specific H-Y antigens found only on the surface of male cells. H-Y antigens are able to elicit an immune reaction when cells or tissues from a male donor are grafted to a female recipient. We describe here the development and testing of an inexpensive approach using polyclonal antibodies against four specific H-Y outer membrane proteins male enhanced antigen 1 (MEA 1), male enhanced antigen 2 (MEA 2), sex determining region Y (SRY) and testis determining factor (TDF). Epitopes based on hydrophilic primary sequences of the proteins were synthesized, N-terminal biotin-labeled, linked to streptavidin and mixed with a Ribi adjuvant prior to immunization in rabbits. The antiserum was tested to determine affinity to swine spermatozoa using anti-motility, flow cytometry and motility and sedimentation chambers. Fluorescent microscopy and fluorescent in situ hybridization (FISH) was used to identify the percentage of motile spermatozoa that contained the Y chromosome. We found that the polyclonal antibodies had high affinity to the spermatozoa leading to a cessation of motility. Furthermore, the majority of these non-motile spermatozoa contained the Y chromosome. We conclude that the use of polyclonal antiserum against synthetic H-Y peptide antigens may be an inexpensive and simple means to inhibit the motility of swine spermatozoa bearing the Y chromosome.
[Mh] Termos MeSH primário: Anticorpos/farmacologia
Epitopos/metabolismo
Fragmentos de Peptídeos/administração & dosagem
Pré-Seleção do Sexo
Espermatozoides/metabolismo
[Mh] Termos MeSH secundário: Animais
Afinidade de Anticorpos
Movimento Celular/efeitos dos fármacos
Esqueleto da Parede Celular/administração & dosagem
Células Cultivadas
Fatores Corda/administração & dosagem
Mapeamento de Epitopos
Epitopos/química
Hibridização in Situ Fluorescente
Lipídeo A/administração & dosagem
Lipídeo A/análogos & derivados
Masculino
Neoplasia Endócrina Múltipla Tipo 1/imunologia
Neoplasia Endócrina Múltipla Tipo 1/metabolismo
Neoplasia Endócrina Múltipla Tipo 2a/imunologia
Neoplasia Endócrina Múltipla Tipo 2a/metabolismo
Fragmentos de Peptídeos/síntese química
Fragmentos de Peptídeos/metabolismo
Pré-Seleção do Sexo/métodos
Proteína da Região Y Determinante do Sexo/imunologia
Proteína da Região Y Determinante do Sexo/metabolismo
Espermatozoides/imunologia
Espermatozoides/patologia
Suínos
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Antibodies); 0 (Cell Wall Skeleton); 0 (Cord Factors); 0 (Epitopes); 0 (Lipid A); 0 (Peptide Fragments); 0 (Ribi adjuvant); 0 (Sex-Determining Region Y Protein)
[Em] Mês de entrada:1108
[Cu] Atualização por classe:110425
[Lr] Data última revisão:
110425
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:110315
[St] Status:MEDLINE
[do] DOI:10.1016/j.jri.2011.01.012


  8 / 124 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:21314815
[Au] Autor:Miyazaki J; Kawai K; Kojima T; Oikawa T; Joraku A; Shimazui T; Nakaya A; Yano I; Nakamura T; Harashima H; Akaza H
[Ad] Endereço:Graduate School of Comprehensive Human Sciences, Department of Urology, University of Tsukuba, Ibaraki, Japan. jmiyazaki@md.tsukuba.ac.jp
[Ti] Título:The liposome-incorporating cell wall skeleton of Mycobacterium bovis bacillus Calmette-Guéin can directly enhance the susceptibility of cancer cells to lymphokine-activated killer cells through up-regulation of natural-killer group 2, member D ligands.
[So] Source:BJU Int;108(9):1520-6, 2011 Nov.
[Is] ISSN:1464-410X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: • To conduct a preclinical evaluation of the ability of natural killer cells to cytolyze bladder cancer cells that were modified to show enhanced expression of natural-killer group 2, member D (NKG2D) ligands by R8-liposome-bacillus Calmette-Guéin (BCG)-cell wall skeleton (CWS) treatment. MATERIALS AND METHODS: • The T24 cells and RT-112 cells were co-cultured with R8-liposome-BCG-CWS and BCG for 2, 4, or 6 h, and then the surface expression of NKG2D ligands was analyzed using TaqMan real-time quantitative RT-PCR. • Peripheral blood mononuclear cells were obtained with a conventional preparation kit, and then lymphokine-activated killer (LAK) cells were generated from these purified peripheral blood mononuclear cells via interleukin-2 stimulation. • The anti-tumour effect of LAK cells against untreated and R8-liposome-BCG-CWS co-cultured with cells of the human bladder cancer cell lines T24 and RT-112 was analyzed using the cytotoxic WST-8 assay method at 4 h of culture at various effector/target (E : T) ratios. RESULTS: • Major histocompatibility complex class I-related chain B (MICB) expression was increased ≈1.5-fold on T24 cells and RT-112 cells with BCG. • UL-16-binding protein (ULBP) 1 expression was also increased ≈1.5-fold on T24 cells and RT-112 cells with BCG. R8-liposome-BCG-CWS increased the surface expression of MICB 2.2-fold on T24 cells but did not increase it significantly on RT-112 cells. • ULBP1 expression was increased ≈2.2-fold on RT-112 cells, although no differences were observed between the expression of ULBP2 and 3 with R8-liposome-BCG-CWS. • T24 cells that were co-cultured with R8-liposome-BCG-CWS showed an ≈1.3-fold increase in sensitivity to cytolysis by LAK cells at an E : T ratio of 4 and RT-112 cells showed an ≈1.4-fold increase at an E : T ratio of 2. CONCLUSIONS: • In the present study, the induction of surface NKG2D ligands by R8-liposome-BCG-CWS rendered cancer cells more susceptible to cytolysis by LAK cells. • T24 cells and RT-112 cells, even when cultured singly in the absence of immune cells, can directly respond to R8-liposome-BCG-CWS. • The results obtained in the present study may therefore indicate a novel adoptive immunotherapy against bladder cancers.
[Mh] Termos MeSH primário: Vacina BCG/farmacologia
Esqueleto da Parede Celular/farmacologia
Células Matadoras Ativadas por Linfocina/imunologia
Células Matadoras Naturais/metabolismo
Neoplasias da Bexiga Urinária/imunologia
[Mh] Termos MeSH secundário: Antígenos de Histocompatibilidade Classe I/metabolismo
Seres Humanos
Ligantes
Mycobacterium bovis/química
Reação em Cadeia da Polimerase em Tempo Real
Células Tumorais Cultivadas/imunologia
Regulação para Cima
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (BCG Vaccine); 0 (Cell Wall Skeleton); 0 (Histocompatibility Antigens Class I); 0 (Ligands); 0 (MHC class I-related chain A); 0 (MICB antigen)
[Em] Mês de entrada:1112
[Cu] Atualização por classe:111025
[Lr] Data última revisão:
111025
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:110215
[St] Status:MEDLINE
[do] DOI:10.1111/j.1464-410X.2010.10056.x


  9 / 124 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:21199899
[Au] Autor:Bemark M; Bergqvist P; Stensson A; Holmberg A; Mattsson J; Lycke NY
[Ad] Endereço:Department of Microbiology and Immunology, Mucosal Immunobiology and Vaccine Center, Institute of Biomedicine, University of Gothenburg, Gothenburg, Sweden.
[Ti] Título:A unique role of the cholera toxin A1-DD adjuvant for long-term plasma and memory B cell development.
[So] Source:J Immunol;186(3):1399-410, 2011 Feb 01.
[Is] ISSN:1550-6606
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Adjuvants have traditionally been appreciated for their immunoenhancing effects, whereas their impact on immunological memory has largely been neglected. In this paper, we have compared three mechanistically distinct adjuvants: aluminum salts (Alum), Ribi (monophosphoryl lipid A), and the cholera toxin A1 fusion protein CTA1-DD. Their influence on long-term memory development was dramatically different. Whereas a single immunization i.p. with 4-hydroxy-3-nitrophenyl acetyl (NP)-chicken γ-globulin and adjuvant stimulated serum anti-NP IgG titers that were comparable at 5 wk, CTA1-DD-adjuvanted responses were maintained for >16 mo with a half-life of anti-NP IgG ∼36 wk, but <15 wk after Ribi or Alum. A CTA1-DD dose-dependent increase in germinal center (GC) size and numbers was found, with >60% of splenic B cell follicles hosting GC at an optimal CTA1-DD dose. Roughly 7% of these GC were NP specific. This GC-promoting effect correlated well with the persistence of long-term plasma cells in the bone marrow and memory B cells in the spleen. CTA1-DD also facilitated increased somatic hypermutation and affinity maturation of NP-specific IgG Abs in a dose-dependent fashion, hence arguing that large GC not only promotes higher Ab titers but also high-quality Ab production. Adoptive transfer of splenic CD80(+), but not CD80(-), B cells, at 1 y after immunization demonstrated functional long-term anti-NP IgG and IgM memory cells. To our knowledge, this is the first report to specifically compare and document that adjuvants can differ considerably in their support of long-term immune responses. Differential effects on the GC reaction appear to be the basis for these differences.
[Mh] Termos MeSH primário: Adjuvantes Imunológicos/fisiologia
Subpopulações de Linfócitos B/citologia
Subpopulações de Linfócitos B/imunologia
Diferenciação Celular/imunologia
Toxina da Cólera/sangue
Toxina da Cólera/fisiologia
Memória Imunológica
[Mh] Termos MeSH secundário: Adjuvantes Imunológicos/sangue
Compostos de Alúmen/metabolismo
Compostos de Alúmen/farmacologia
Animais
Subpopulações de Linfócitos B/metabolismo
Esqueleto da Parede Celular/sangue
Esqueleto da Parede Celular/fisiologia
Fatores Corda/sangue
Fatores Corda/fisiologia
Relação Dose-Resposta Imunológica
Feminino
Centro Germinativo/imunologia
Centro Germinativo/metabolismo
Imunoglobulina A/biossíntese
Imunoglobulina A/sangue
Imunoglobulina G/biossíntese
Imunoglobulina G/sangue
Lipídeo A/análogos & derivados
Lipídeo A/sangue
Lipídeo A/fisiologia
Camundongos
Camundongos Endogâmicos C57BL
Dados de Sequência Molecular
Plasmócitos/citologia
Plasmócitos/imunologia
Plasmócitos/metabolismo
Proteínas Recombinantes de Fusão/sangue
Proteínas Recombinantes de Fusão/fisiologia
Fatores de Tempo
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Adjuvants, Immunologic); 0 (Alum Compounds); 0 (CTA1-DD protein, recombinant); 0 (Cell Wall Skeleton); 0 (Cord Factors); 0 (Immunoglobulin A); 0 (Immunoglobulin G); 0 (Lipid A); 0 (Recombinant Fusion Proteins); 0 (Ribi adjuvant); 34S289N54E (aluminum sulfate); 9012-63-9 (Cholera Toxin)
[Em] Mês de entrada:1103
[Cu] Atualização por classe:161125
[Lr] Data última revisão:
161125
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:110105
[St] Status:MEDLINE
[do] DOI:10.4049/jimmunol.1002881


  10 / 124 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
[PMID]:21036724
[Au] Autor:Kato T; Bilim V; Yuuki K; Naito S; Yamanobe T; Nagaoka A; Yano I; Akaza H; Tomita Y
[Ad] Endereço:Department of Urology, Yamagata University School of Medicine, Yamagata, Japan.
[Ti] Título:Bacillus Calmette-Guerin and BCG cell wall skeleton suppressed viability of bladder cancer cells in vitro.
[So] Source:Anticancer Res;30(10):4089-96, 2010 Oct.
[Is] ISSN:1791-7530
[Cp] País de publicação:Greece
[La] Idioma:eng
[Ab] Resumo:AIM: Bacillus Calmette-Guerin (BCG) is one of therapeutic options for urothelial carcinoma (UC). The objectives of this study were to determine the direct effect of viable or heat-killed BCG and BCG cell wall skeleton (BCG-CWS) on UC cells in vitro. MATERIALS AND METHODS: UC cell lines were co-cultured with viable or heat-killed BCG Immunobladder® (Tokyo 172 strain) and BCG-CWS. Viability of the cells, apoptosis and BrdU incorporation were estimated. RESULTS: BCG induced cell growth retardation in highly malignant UC bearing integrin α5ß1 (VLA5). VLA5-blocking antibody partially abrogated this effect. BCG treatment induced a modest increase in the sub-G(1) fraction of cells and a decrease of BrdU incorporation. Cell growth retardation effect of viable BCG was reproduced by both heat-killed BCG and BCG-CWS. CONCLUSION: The results indicate that VLA5 may be a biomarker of UC with sensitivity to BCG. Moreover, BCG-CWS is a promising substance which might replace BCG, preventing life-threatening complications of viable BCG treatment.
[Mh] Termos MeSH primário: Vacina BCG/farmacologia
Mycobacterium bovis/imunologia
Neoplasias da Bexiga Urinária/terapia
[Mh] Termos MeSH secundário: Processos de Crescimento Celular/imunologia
Linhagem Celular Tumoral
Esqueleto da Parede Celular/imunologia
Esqueleto da Parede Celular/farmacologia
Quinase 1 de Adesão Focal/biossíntese
Quinase 1 de Adesão Focal/imunologia
Fase G1/imunologia
Seres Humanos
Integrina alfa5beta1/biossíntese
Integrina alfa5beta1/imunologia
Transdução de Sinais
Receptor 2 Toll-Like/biossíntese
Receptor 2 Toll-Like/imunologia
Receptor 4 Toll-Like/biossíntese
Receptor 4 Toll-Like/imunologia
Neoplasias da Bexiga Urinária/imunologia
Neoplasias da Bexiga Urinária/patologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (BCG Vaccine); 0 (Cell Wall Skeleton); 0 (Integrin alpha5beta1); 0 (TLR2 protein, human); 0 (TLR4 protein, human); 0 (Toll-Like Receptor 2); 0 (Toll-Like Receptor 4); EC 2.7.10.2 (Focal Adhesion Kinase 1); EC 2.7.10.2 (PTK2 protein, human)
[Em] Mês de entrada:1012
[Cu] Atualização por classe:121115
[Lr] Data última revisão:
121115
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:101102
[St] Status:MEDLINE



página 1 de 13 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde